In HNSCC, EMT induced by TGF-β signaling mediates immunosuppression and activation of immune checkpoints, such as PD-1, PD-L1, and CTLA-4, particularly in cells with mesenchymal phenotypes. The gene discussed is TGFB1; the disease is head and neck squamous cell carcinoma.